Newsfeeds - Spark Newswire

1 minute read

Compugen’s Out-Licensed Lung Cancer Candidate Enters Human Trial

Today, 10:37 AM

AstraZeneca Plc’s (NASDAQ:AZN) bispecific antibody derived from Compugen Ltd’s (NASDAQ:CGEN) COM902 will advance into clinical development. AstraZeneca plans to initiate a Phase…

AZN

2 minute read

Compugen Announces Bispecific Antibody Derived From COM902 To Enter Clinical Development

By Bill Haddad

Today, 10:37 AM

Compugen Ltd. (NASDAQ:CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that a bispecific antibody of AstraZeneca derived from COM902,

AZN

20 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 10:37 AM

Tuesday morning, 282 companies set new 52-week lows.

AAOI

9 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 10:37 AM

Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.

ABCL

2 minute read

News

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo and Bristol Myers Squibb’s Anti-TIGIT Antibody, BMS-986207

By Benzinga Newsdesk

Today, 10:37 AM

Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the cohort expansion arm of the Phase

CGEN

2 minute read

News

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

By Benzinga Newsdesk

Today, 10:37 AM

Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first patient has been dosed in its Phase 1 clinical study evaluating the

CGEN

1 minute read

Compugen Doses First Patient In COM701/Opdivo Phase 1b Cohort Expansion Study

By Bill Haddad

Today, 10:37 AM

CGEN

4 minute read

45 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:37 AM

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

ADIL

3 minute read

36 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 10:37 AM

Gainers Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

ADIL

14 minute read

Uncategorized

Earnings Scheduled For May 13, 2021

By Benzinga Insights

Today, 10:37 AM

Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.

AACG